7432-s and Sinusitis

Acute sinusitis is a common childhood illness. If it is overlooked or undertreated, suppurative and intracranial complications may develop. Amoxicillin has traditionally been the antibiotic of choice for treatment of acute sinusitis. However, the efficacy of amoxicillin has been reduced because of the emergence of bacteria producing b-lactamase and altered penicillin-binding proteins. This study compares the effectiveness of 10, 15, and 20 days of ceftibuten therapy with 14 days of erythromycin-sulfisoxazole therapy in treating acute sinusitis. The results indicate that both treatment regimens are effective in treating acute sinusitis (96% clinical response for erythromycin-sulfisoxazole vs 92% for a 10- or 15-day course of ceftibuten vs 100% for a 20-day course of ceftibuten). Longer treatment periods may be more effective in resolving the acute illness.

Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Ceftibuten; Cephalosporins; Child; Child, Preschool; Erythromycin; Female; Humans; Infant; Male; Sinusitis; Sulfisoxazole

The efficacy and safety of a once-daily oral regimen of 400 mg ceftibuten was compared with oral co-amoxiclav 500 mg three times daily in a multicentre, single-blind study. In patients with a bacteriologically confirmed infection, a successful clinical outcome was reported in 25 of 25 patients treated with ceftibuten and 10 of 10 patients treated with co-amoxiclav. In a further group of 88 patients, most of whom had been excluded from the primary efficacy evaluation because no pathogen was isolated pretreatment, overall successful clinical outcomes of 87% and 88% were reported for ceftibuten and co-amoxiclav, respectively. The duration of treatment and the time to resolution of the signs and symptoms of sinusitis were not significantly different in the two treatment groups. The incidence of adverse events was higher in the co-amoxiclav-treated patients (31% versus 15% in the ceftibuten group) as was the incidence of severe events (10% for co-amoxiclav-treated patients versus < 1% in the ceftibuten group). In summary, once-daily ceftibuten can be considered a safe and effective treatment for acute bacterial sinusitis.

Topics: Acute Disease; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Ceftibuten; Cephalosporins; Clavulanic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Single-Blind Method; Sinusitis

Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cefazolin; Ceftibuten; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nasal Polyps; Ofloxacin; Prospective Studies; Sinusitis; Sulbactam

Topics: Acute Disease; Bacterial Infections; Ceftibuten; Cephalosporins; Chronic Disease; Clavulanic Acid; Drug Resistance, Multiple; Humans; Mometasone Furoate; Penicillanic Acid; Pregnadienediols; Sinusitis; Treatment Outcome

The aim of the study was to substantiate clinically and microbiologically administration of such oral cephalosporins as cefuroxime axetil and ceftibuten in acute sinusitis. The spectrum of causative agents of acute sinusitis was determined, most common pathogens were identified and their sensitivity to antibiotics was tested. The conclusion is made that cephalosporins of the II-III generation meet the requirements to antibacterial drugs for treatment of acute sinusitis.

Topics: Acute Disease; Adult; Ceftibuten; Cefuroxime; Cephalosporins; Drug Tolerance; Female; Humans; Male; Sinusitis; Treatment Outcome

Topics: Administration, Topical; Bacterial Infections; Ceftibuten; Cephalosporins; Drug Therapy, Combination; Humans; Mometasone Furoate; Pregnadienediols; Sinusitis